应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06127 昭衍新药
休市中 04-19 16:08:35
9.170
-0.370
-3.88%
最高
9.360
最低
9.120
成交量
64.32万
今开
9.250
昨收
9.540
日振幅
2.52%
总市值
68.76亿
流通市值
10.91亿
总股本
7.50亿
成交额
591.27万
换手率
0.54%
流通股本
1.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
智通AH统计|4月19日
智通财经 · 04-19 16:15
智通AH统计|4月19日
胡涛2024年一季度表现,嘉实远见企业精选两年持有期混合基金季度跌幅5.24%
证券之星 · 04-19 09:30
胡涛2024年一季度表现,嘉实远见企业精选两年持有期混合基金季度跌幅5.24%
医疗服务行业盘中拉升,昭衍新药涨6.38%
自选股智能写手 · 04-17
医疗服务行业盘中拉升,昭衍新药涨6.38%
港股异动 | 昭衍新药(06127)跌超6%领跌CRO概念 美联储加息可能性仍存 国内创新药仍处调整周期
智通财经 · 04-16
港股异动 | 昭衍新药(06127)跌超6%领跌CRO概念 美联储加息可能性仍存 国内创新药仍处调整周期
CRO概念盘中跳水,昭衍新药跌2.70%
自选股智能写手 · 04-16
CRO概念盘中跳水,昭衍新药跌2.70%
昭衍新药盘中异动 早盘急速跳水5.16%报9.361港元
自选股智能写手 · 04-16
昭衍新药盘中异动 早盘急速跳水5.16%报9.361港元
昭衍新药04月15日遭主力抛售52万元 环比增加116.67%
自选股智能写手 · 04-15
昭衍新药04月15日遭主力抛售52万元 环比增加116.67%
智通AH统计|4月15日
智通财经 · 04-15
智通AH统计|4月15日
昭衍新药盘中异动 股价大涨5.26%
自选股智能写手 · 04-15
昭衍新药盘中异动 股价大涨5.26%
昭衍新药04月11日主力资金流出123万元 连续3日减仓
自选股智能写手 · 04-11
昭衍新药04月11日主力资金流出123万元 连续3日减仓
里昂:升泰格医药(03347)及昭衍新药(06127)评级至“跑赢大市” 上调目标价
智通财经 · 04-11
里昂:升泰格医药(03347)及昭衍新药(06127)评级至“跑赢大市” 上调目标价
北向资金4月10日净买入昭衍新药22.50万股 连续5日增持
自选股智能写手 · 04-11
北向资金4月10日净买入昭衍新药22.50万股 连续5日增持
生物疫苗概念盘中拉升,昭衍新药涨1.16%
自选股智能写手 · 04-10
生物疫苗概念盘中拉升,昭衍新药涨1.16%
昭衍新药获融资买入0.23亿元,近三日累计买入0.64亿元
金融界 · 04-10
昭衍新药获融资买入0.23亿元,近三日累计买入0.64亿元
太平洋:给予昭衍新药买入评级
证券之星 · 04-09
太平洋:给予昭衍新药买入评级
4月9日昭衍新药涨9.98%,嘉实优质精选混合A基金重仓该股
证券之星 · 04-09
4月9日昭衍新药涨9.98%,嘉实优质精选混合A基金重仓该股
昭衍新药涨9.98%,中国银河一周前给出“买入”评级
证券之星 · 04-09
昭衍新药涨9.98%,中国银河一周前给出“买入”评级
涨停揭秘 | 昭衍新药首板涨停,封板资金6286.29万元
金融界 · 04-09
涨停揭秘 | 昭衍新药首板涨停,封板资金6286.29万元
4月9日昭衍新药涨停分析:基因编辑,医药,创新药概念热股
证券之星 · 04-09
4月9日昭衍新药涨停分析:基因编辑,医药,创新药概念热股
加载更多
公司概况
公司名称:
昭衍新药
所属市场:
SEHK
上市日期:
--
主营业务:
北京昭衍新药研究中心股份有限公司是一家主要从事新药药理毒理学研究的中国公司。非临床研究服务包括药物安全性评价、药代动力学研究以及药理和药效学研究。临床试验及相关服务包括临床合同研究组织服务、一期临床研究协作单位 (CRU),以及生物分析服务。实验模型业务主要包括啮齿类及非人灵长类动物。该公司在国内和海外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":9.17,"timestamp":1713514115035,"preClose":9.54,"halted":0,"volume":643239,"delay":0,"floatShares":118995206,"shares":749888699,"eps":0.572358,"marketStatus":"休市中","marketStatusCode":7,"change":-0.37,"latestTime":"04-19 16:08:35","open":9.25,"high":9.36,"low":9.12,"amount":5912737,"amplitude":0.025157,"askPrice":9.25,"askSize":200,"bidPrice":9.17,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":0.5723579948155283,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713749400000},"adr":0,"listingDate":1614268800000,"adjPreClose":9.54,"dividendRate":0.018845,"openAndCloseTimeList":[[1713490200000,1713499200000],[1713502800000,1713513600000]],"volumeRatio":0.5097277448624983,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06127","defaultTab":"news","newsList":[{"id":"2428858687","title":"智通AH统计|4月19日","url":"https://stock-news.laohu8.com/highlight/detail?id=2428858687","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428858687?lang=zh_cn&edition=full","pubTime":"2024-04-19 16:15","pubTimestamp":1713514507,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,截止4月19日收盘,东北电气、弘业期货、浙江世宝分列AH溢价率前三位,溢价率分别为1167.61%、748.78%、631.25%;招商银行、比亚迪股份、紫金矿业分列AH溢价率末三位,溢价率分别为23.72%、25.09%、25.82%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1105299.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428576994","title":"胡涛2024年一季度表现,嘉实远见企业精选两年持有期混合基金季度跌幅5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428576994","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2428576994?lang=zh_cn&edition=full","pubTime":"2024-04-19 09:30","pubTimestamp":1713490236,"startTime":"0","endTime":"0","summary":"证券之星消息,截止2024年一季度末,基金经理胡涛旗下共管理7只基金,本季度表现最佳的为嘉实远见企业精选两年持有期混合,季度净值跌5.24%。胡涛在担任嘉实优质企业混合基金经理的任职期间累计任职回报67.66%,平均年化收益率为5.49%。持有期间的估算收益率为95.07%,持有期间东华软件在2014年到2015年的年报归属净利润增幅达9.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024041900017336.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2428233456","title":"医疗服务行业盘中拉升,昭衍新药涨6.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428233456","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428233456?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:44","pubTimestamp":1713318269,"startTime":"0","endTime":"0","summary":"04月17日,医疗服务行业盘中拉升,截至09点44分,医疗服务行业整体指数上涨2.02%,报4532.820点。从个股上来看,该行业的成分股中,昭衍新药涨6.38%,兰卫医学、成都先导等6只股涨幅超过5%。从资金上来看,截止发稿,医疗服务行业主力净流入为-897.05万,其中爱尔眼科受到资金热捧,主力净流入1568.37万;拉长时间线来看,该板块近20日主力资金净流入-157.16亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041709442987e811c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041709442987e811c9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427818909","title":"港股异动 | 昭衍新药(06127)跌超6%领跌CRO概念 美联储加息可能性仍存 国内创新药仍处调整周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2427818909","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427818909?lang=zh_cn&edition=full","pubTime":"2024-04-16 14:37","pubTimestamp":1713249456,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,CRO概念股继续走低,截至发稿,昭衍新药跌5.98%,报9.28港元;泰格医药跌5.93%,报30.15港元;康龙化成跌5.18%,报8.78港元;药明康德跌3.96%,报32.75港元。消息面上,瑞银策略师表示,顽固的通胀和经济强劲增长提高了美联储加息而不是降息的可能性,明年利率最高可能升至6.5%。此外,近日有媒体报道,美国生物安全法案所覆盖的企业名单可能会覆盖更多的中国CRO/CDMO企业。该行认为,海外需求将先于本土需求改善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103172.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427652928","title":"CRO概念盘中跳水,昭衍新药跌2.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427652928","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427652928?lang=zh_cn&edition=full","pubTime":"2024-04-16 10:03","pubTimestamp":1713233001,"startTime":"0","endTime":"0","summary":"04月16日,CRO概念盘中跳水,截至10点03分,CRO概念整体指数下跌5.05%,报345.950点。从个股上来看,该概念的成分股中,昭衍新药跌2.70%,泰格医药、诺泰生物、博腾股份跌幅居前。从资金上来看,截止发稿,CRO概念主力净流入为-2.02亿,其中华测检测受到资金热捧,主力净流入559.41万;拉长时间线来看,该板块近20日主力资金净流入-133.07亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161003217a52fd3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161003217a52fd3b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427868965","title":"昭衍新药盘中异动 早盘急速跳水5.16%报9.361港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427868965","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427868965?lang=zh_cn&edition=full","pubTime":"2024-04-16 09:50","pubTimestamp":1713232212,"startTime":"0","endTime":"0","summary":"2024年04月16日早盘09时50分,昭衍新药股票出现波动,股价快速跳水5.16%。截至发稿,该股报9.361港元/股,成交量4.9274万股,换手率0.04%,振幅3.44%。资金方面,该股资金流入15.9119万港元,流出23.8949万港元。昭衍新药股票所在的生物技术行业中,整体跌幅为0.28%。其相关个股中,奥星生命科技、正大企业国际、和铂医药-B涨幅较大,振幅较大的相关个股有来凯医药-B、圣诺医药-B、科济药业-B,振幅分别为14.21%、11.10%、7.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416095012861e5fce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416095012861e5fce&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427145025","title":"昭衍新药04月15日遭主力抛售52万元 环比增加116.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427145025","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427145025?lang=zh_cn&edition=full","pubTime":"2024-04-15 16:15","pubTimestamp":1713168926,"startTime":"0","endTime":"0","summary":"04月15日, 昭衍新药股价涨6.02%,报收9.87元,成交金额839万元,换手率0.75%,振幅8.38%,量比0.66。昭衍新药今日主力资金净流出52万元,连续5日净流出,上一交易日主力净流出24万元,今日环比增加116.67%。该股近5个交易日上涨6.65%,主力资金累计净流出369万元;近20日主力资金累计净流入9万元,其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404151615478b2526bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404151615478b2526bb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427802372","title":"智通AH统计|4月15日","url":"https://stock-news.laohu8.com/highlight/detail?id=2427802372","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427802372?lang=zh_cn&edition=full","pubTime":"2024-04-15 16:15","pubTimestamp":1713168905,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,截止4月15日收盘,东北电气、弘业期货、浙江世宝分列AH溢价率前三位,溢价率分别为1155.81%、750.00%、640.00%;比亚迪股份、招商银行、紫金矿业分列AH溢价率末三位,溢价率分别为22.90%、23.84%、24.63%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1102475.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2427236350","title":"昭衍新药盘中异动 股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427236350","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427236350?lang=zh_cn&edition=full","pubTime":"2024-04-15 15:59","pubTimestamp":1713167972,"startTime":"0","endTime":"0","summary":"2024年04月15日临近收盘15时59分,昭衍新药股票出现异动,股价急速上涨5.26%。截至发稿,该股报9.801港元/股,成交量86.3902万股,换手率0.73%,振幅7.41%。资金方面,该股资金流入420.977万港元,流出215.506万港元。昭衍新药股票所在的生物技术行业中,整体跌幅为0.88%。消息层面,截至15时59分,《股价多次遭美法案进度扰动 昭衍新药:未来扩展其他海外客户降低风险|直击业绩会》资讯为影响昭衍新药的重要信息。针对药明系被美法案牵涉事件,公司会密切关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415155933861e5c4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415155933861e5c4d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426238578","title":"昭衍新药04月11日主力资金流出123万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2426238578","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426238578?lang=zh_cn&edition=full","pubTime":"2024-04-11 16:15","pubTimestamp":1712823332,"startTime":"0","endTime":"0","summary":"04月11日, 昭衍新药股价跌0.81%,报收9.75元,成交金额1066万元,换手率0.93%,振幅4.07%,量比0.83。昭衍新药今日主力资金净流出123万元,连续3日净流出,上一交易日主力净流出70万元,今日环比增加75.71%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为77.78%,平均跌幅为3.45%。该股近5个交易日上涨5.41%,主力资金累计净流出249万元;近20日主力资金累计净流入81万元,其中净流入天数为8日。该股主力净额占比0.11%,港股市场排名2610/2628。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041116154787667900&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041116154787667900&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426788289","title":"里昂:升泰格医药(03347)及昭衍新药(06127)评级至“跑赢大市” 上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2426788289","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426788289?lang=zh_cn&edition=full","pubTime":"2024-04-11 15:12","pubTimestamp":1712819563,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,里昂发布研究报告称,上调泰格医药(03347) 评级由“跑输大市”升为“跑赢大市”,因料其自2025财年盈增长透明度将改善,目标价由31.4港元升至37.3港元。该行亦昭衍新药(06127)评级由“跑输大市”升为“跑赢大市”,目标价由9.8港元升至11港元。报告指出,内地近几周不断有对于创新药物的政策出台,见到投资者对创新药物厂商的信心有所改善。在内地临床研究业之中,该行认为,泰格医药及昭衍新药比起同业更可受惠于政府的新支持政策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1101040.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426547944","title":"北向资金4月10日净买入昭衍新药22.50万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2426547944","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426547944?lang=zh_cn&edition=full","pubTime":"2024-04-11 09:30","pubTimestamp":1712799028,"startTime":"0","endTime":"0","summary":"4月10日, 北向资金增持昭衍新药22.50万股,连续5日增持。截止当日收盘,沪股通共持有昭衍新药969.49万股,占流通股1.53%。沪股通增持金额前五个股分别为工业富联、济川药业、中国平安、兴业银行、福莱特。昭衍新药近5个交易日上涨1.80%,沪股通累计增持131.94万股;近20个交易日上涨8.11%,沪股通累计减持110.17万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110933518b0d60f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110933518b0d60f2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426436467","title":"生物疫苗概念盘中拉升,昭衍新药涨1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426436467","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426436467?lang=zh_cn&edition=full","pubTime":"2024-04-10 14:25","pubTimestamp":1712730355,"startTime":"0","endTime":"0","summary":"04月10日,生物疫苗概念盘中拉升,截至14点25分,生物疫苗概念整体指数上涨0.50%,报1933.330点。从个股上来看,该概念的成分股中,昭衍新药涨1.16%,梅花生物、海普瑞、君正集团涨幅居前。从资金上来看,截止发稿,生物疫苗概念主力净流入为-2.77亿,其中梅花生物受到资金热捧,主力净流入4504.66万;拉长时间线来看,该板块近20日主力资金净流入-17.32亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041014255587e7f35b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041014255587e7f35b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426174433","title":"昭衍新药获融资买入0.23亿元,近三日累计买入0.64亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426174433","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426174433?lang=zh_cn&edition=full","pubTime":"2024-04-10 08:11","pubTimestamp":1712707902,"startTime":"0","endTime":"0","summary":"4月9日,沪深两融数据显示,昭衍新药获融资买入额0.23亿元,居两市第302位,当日融资偿还额0.41亿元,净卖出1861.28万元。最近三个交易日,3日-9日,昭衍新药分别获融资买入0.16亿元、0.25亿元、0.23亿元。融券方面,当日融券卖出25.07万股,净卖出22.56万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240410081153875ca24b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240410081153875ca24b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426716931","title":"太平洋:给予昭衍新药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2426716931","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2426716931?lang=zh_cn&edition=full","pubTime":"2024-04-09 18:32","pubTimestamp":1712658728,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司周豫近期对昭衍新药进行研究并发布了研究报告《海外业务增速亮眼,新签项目数环比改善》,本报告对昭衍新药给出买入评级,当前股价为18.96元。最新盈利预测明细如下:该股最近90天内共有10家机构给出评级,买入评级6家,增持评级4家;过去90天内机构目标均价为20.67。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024040900033617.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426152382","title":"4月9日昭衍新药涨9.98%,嘉实优质精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426152382","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2426152382?lang=zh_cn&edition=full","pubTime":"2024-04-09 16:57","pubTimestamp":1712653064,"startTime":"0","endTime":"0","summary":"证券之星消息,4月9日昭衍新药涨9.98%,收盘报18.96元,换手率3.02%,成交量19.05万手,成交额3.46亿元。根据2023基金年报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为嘉实优质精选混合A。嘉实优质精选混合A目前规模为8.26亿元,最新净值0.5168,较上一交易日下跌1.66%,近一年下跌25.24%。嘉实优质精选混合A的前十大重仓股如下:以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024040900028896.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426152335","title":"昭衍新药涨9.98%,中国银河一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2426152335","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2426152335?lang=zh_cn&edition=full","pubTime":"2024-04-09 16:57","pubTimestamp":1712653047,"startTime":"0","endTime":"0","summary":"今日昭衍新药涨9.98%,收盘报18.96元。2024年4月1日,中国银河研究员程培,闫晓松发布了对昭衍新药的研报《公司整体运营稳健,利润阶段性承压》,该研报对昭衍新药给出“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为中国银河的程培。昭衍新药个股概况:以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024040900028891.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426217159","title":"涨停揭秘 | 昭衍新药首板涨停,封板资金6286.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426217159","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426217159?lang=zh_cn&edition=full","pubTime":"2024-04-09 16:34","pubTimestamp":1712651667,"startTime":"0","endTime":"0","summary":"4月9日,昭衍新药收盘首板涨停,截至当日收盘,昭衍新药报18.96元/股,成交额3.46亿元,总市值142.18亿元,封板资金6286.29万元。目前,公司已经建立了体外和体内药效筛选评价平台以及早期成药性筛选评价平台,为创新药企提供早期发现服务。业绩方面,2023年1月-12月,昭衍新药实现营业收入23.76亿元,同比增长4.78%;归属净利润3.97亿元,同比减少63.04%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091634388758f479&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091634388758f479&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426155313","title":"4月9日昭衍新药涨停分析:基因编辑,医药,创新药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426155313","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2426155313?lang=zh_cn&edition=full","pubTime":"2024-04-09 15:54","pubTimestamp":1712649286,"startTime":"0","endTime":"0","summary":"证券之星消息,昭衍新药涨停收盘,收盘价18.96元。近5日资金流向一览见下表:该股为基因编辑,医药,创新药概念热股,当日基因编辑概念上涨3.8%,医药概念上涨2.66%,创新药概念上涨2.63%。以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等,如存在问题请联系我们。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024040900023940.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0546},{"period":"3month","weight":-0.1885},{"period":"6month","weight":-0.3167},{"period":"1year","weight":-0.6042},{"period":"ytd","weight":-0.2869}],"compareEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":-0.0193},{"period":"3month","weight":0.0598},{"period":"6month","weight":-0.0552},{"period":"1year","weight":-0.2046},{"period":"ytd","weight":-0.0483}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京昭衍新药研究中心股份有限公司是一家主要从事新药药理毒理学研究的中国公司。非临床研究服务包括药物安全性评价、药代动力学研究以及药理和药效学研究。临床试验及相关服务包括临床合同研究组织服务、一期临床研究协作单位 (CRU),以及生物分析服务。实验模型业务主要包括啮齿类及非人灵长类动物。该公司在国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.116163},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.004244},{"month":3,"riseRate":0.25,"avgChangeRate":-0.02162},{"month":4,"riseRate":0.25,"avgChangeRate":-0.041513},{"month":5,"riseRate":0.666667,"avgChangeRate":0.032398},{"month":6,"riseRate":0.666667,"avgChangeRate":0.066228},{"month":7,"riseRate":1,"avgChangeRate":0.051077},{"month":8,"riseRate":0,"avgChangeRate":-0.202169},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.126744},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.049121},{"month":11,"riseRate":0.333333,"avgChangeRate":0.093591},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.082054}],"exchange":"SEHK","name":"昭衍新药","nameEN":"JOINN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,06127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}